<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Chromosomal abnormalities provide clinical utility in the diagnosis and treatment of <z:e sem="disease" ids="C0376545" disease_type="Neoplastic Process" abbrv="">hematologic malignancies</z:e>, and may be predictive of <z:e sem="disease" ids="C1608408" disease_type="Neoplastic Process" abbrv="">malignant transformation</z:e> in individuals without apparent clinical presentation of a <z:e sem="disease" ids="C0376545" disease_type="Neoplastic Process" abbrv="">hematologic cancer</z:e> </plain></SENT>
<SENT sid="1" pm="."><plain>In an effort to confirm previous reports of an association between clonal mosaicism and incident <z:e sem="disease" ids="C0376545" disease_type="Neoplastic Process" abbrv="">hematologic cancer</z:e>, we applied the anomDetectBAF algorithm to call chromosomal anomalies in genotype data from previously conducted Genome Wide Association Studies (GWAS) </plain></SENT>
<SENT sid="2" pm="."><plain>The genotypes were initially collected from DNA derived from peripheral blood of 12,176 participants in the Group Health electronic Medical Records and Genomics study (eMERGE) and the Women's Health Initiative (WHI) </plain></SENT>
<SENT sid="3" pm="."><plain>We detected clonal mosaicism in 169 individuals (1.4%) and large clonal mosaic events (&gt;2 mb) in 117 (1.0%) individuals </plain></SENT>
<SENT sid="4" pm="."><plain>Though only 9.5% of clonal mosaic carriers had an incident diagnosis of <z:e sem="disease" ids="C0376545" disease_type="Neoplastic Process" abbrv="">hematologic cancer</z:e> (<z:hpo ids='HP_0006775'>multiple myeloma</z:hpo>, <z:hpo ids='HP_0002863'>myelodysplastic syndrome</z:hpo>, <z:hpo ids='HP_0002665'>lymphoma</z:hpo>, or <z:hpo ids='HP_0001909'>leukemia</z:hpo>), the carriers had a 5.5-fold increased risk (95% CI: 3.3-9.3; p-value = 7.5×10(-11)) of developing these <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancers</z:e> subsequently </plain></SENT>
<SENT sid="5" pm="."><plain>Carriers of large mosaic anomalies showed particularly pronounced risk of subsequent <z:hpo ids='HP_0001909'>leukemia</z:hpo> (HR = 19.2, 95% CI: 8.9-41.6; p-value = 7.3×10(-14)) </plain></SENT>
<SENT sid="6" pm="."><plain>Thus we independently confirm the association between detectable clonal mosaicism and <z:e sem="disease" ids="C0376545" disease_type="Neoplastic Process" abbrv="">hematologic cancer</z:e> found previously in two recent publications </plain></SENT>
</text></document>